Vivo Bio Tech posts Q4 loss, auditor flags ₹4.19 cr in overdue dues
A ₹6.97 cr deferred tax charge turned Q4 into a loss. The auditor flagged ₹4.19 cr in overdue statutory dues.
— 1 earlier story on Vivo Bio Tech Ltd. →What's new
- Vivo Bio Tech swung to a Q4 net loss of ₹5.44 cr, from a profit of ₹1.26 cr a year earlier.
- Full-year revenue rose to ₹52.6 cr from ₹46.7 cr, but net profit turned into a loss of ₹1.94 cr.
- The auditor flagged ₹4.19 cr in overdue statutory dues, including provident fund and tax deductions.
Why this matters
Revenue grew, but the bottom line swung from a ₹7.57 cr profit to a ₹1.94 cr loss for the full year. The auditor's flag on overdue dues is a compliance red flag for a company posting losses. The board is also moving ahead with a consultant for a proposed merger with Shri Shri Resorts.
What we're watching
- The timeline and rationale for the proposed amalgamation with Shri Shri Resorts.
- Whether the overdue statutory dues are cleared in the next quarter.
- The cost structure of the CRO business in FY27, post the Q4 tax charge.
The full read
Vivo Bio Tech grew revenue to ₹52.6 cr in FY26. It still lost money. A ₹6.97 cr deferred tax charge in Q4 produced a ₹5.44 cr quarterly loss, reversing a ₹1.26 cr profit the year before. The full-year result swung from a ₹7.57 cr profit to a ₹1.94 cr loss. The auditor's report is the bigger problem. It flagged ₹4.19 cr in overdue statutory dues. That's a compliance failure, not just a cash-flow issue. The board is now hiring a consultant for a proposed merger with Shri Shri Resorts, a deal first mentioned in May. A CRO merging with a resort company raises more questions than the results themselves.
Questions answered
- Why did Vivo Bio Tech swing to a quarterly loss?
- A ₹6.97 cr deferred tax charge wiped out Q4 operating profits. The company also cited higher costs in the quarter. Revenue for the full year still grew to ₹52.6 cr from ₹46.7 cr.
- What did the auditor flag?
- The auditor's report flagged ₹4.19 cr in overdue statutory dues, including payments for provident fund and tax deductions. For a company that posted a full-year loss, this is a material compliance issue.
- What is the proposed deal with Shri Shri Resorts?
- The board approved hiring a consultant to advise on a proposed amalgamation with Shri Shri Resorts Private Ltd, a step first disclosed in late May. The filing provides no details on the strategic rationale or deal structure.
- How did the full-year results compare to the prior year?
- Full-year revenue rose to ₹52.6 cr from ₹46.7 cr, but the bottom line swung from a ₹7.57 cr profit to a ₹1.94 cr loss. The reversal is tied to the Q4 deferred tax charge.
Story so far
All notes on VIVOBIOT →- 30 May 2026 · 10:46 PM IST Vivo Bio Tech posts Q4 loss, auditor flags ₹4.19 cr in overdue dues
- 5d ago Vivo Bio Tech plans to merge with Shri Shri Resorts